FindTrial
Sign In

Carrelizumab

DRUG5 trials

Sponsors

Union Hospital, Tongji Medical College, Huazhong University of Science and Technology, Qilu Pharmaceutical Co., Ltd., Fudan University, First Affiliated Hospital Xi'an Jiaotong University, The First Affiliated Hospital with Nanjing Medical University

Conditions

Advanced Breast CancerBreast CancerBreast NeoplasmCholangiocarcinomaEsophageal Squamous Cell CarcinomaHER2-negative Breast CancerHormone Receptor Positive TumorNasopharyngeal Carcinoma

Phase 2

Neoadjuvant Immunotherapy and Chemotherapy Followed by Surgery in Unresectable Stage Ⅲ NSCLC
NCT04943029
Union Hospital, Tongji Medical College, Huazhong University of Science and TechnologyNon Small Cell Lung Cancer
Start: 2021-08-20End: 2024-08-01Target: 30Updated: 2021-09-02
A Phase II/III Trial to Evaluate the Efficacy and Safety of QL1706 in Patients With Nasopharyngeal Carcinoma
NCT05576272
Qilu Pharmaceutical Co., Ltd.Nasopharyngeal Carcinoma
Start: 2022-05-19End: 2024-12-30Target: 460Updated: 2023-11-22
SNF Platform Study of HR+/ HER2-advanced Breast Cancer
RecruitingNCT05594095
Fudan UniversityAdvanced Breast Cancer, Breast Cancer, Breast Neoplasm +2
Start: 2022-12-30End: 2026-12-01Target: 620Updated: 2024-10-04

Unknown Phase

Carlizumab Plus Sovantinib in Second-line Treatment of Advanced or Metastatic Cholangiocarcinoma
NCT05697237
First Affiliated Hospital Xi'an Jiaotong UniversityCholangiocarcinoma
Start: 2023-01-31End: 2024-12-31Target: 60Updated: 2023-01-25
Carrelizumab Combined With Concurrent Radiotherapy and Chemotherapy for Unresectable Esophageal Squamous Cell Carcinoma
Enrolling by invitationNCT06048926
The First Affiliated Hospital with Nanjing Medical UniversityEsophageal Squamous Cell Carcinoma
Start: 2022-07-30End: 2028-07-30Target: 30Updated: 2023-09-21

Related Papers

Precision treatment with artificial intelligence assisted subtyping enhances therapeutic efficacy in HR+/HER2- breast cancer: The LINUXtrial.
2025-12-04
Abstract P2-09-17: Precision medicine based on similarity network fusion (SNF) subtypes of multi-omics in CDK4/6 inhibitor failed HR+/ HER2- advanced breast cancer: the Linux trial
Clinical Cancer Research2025-06-13
Tremelimumab plus Durvalumab prior to Chemoradiotherapy in Unresectable, Locally Advanced Non–Small Cell Lung Cancer: The Induction Trial
Clinical Cancer Research2025-01-172 citations
Safety and efficacy of iparomlimab and tuvonralimab in combination with gemcitabine and cisplatin as first-line treatment for patients with recurrent or metastatic nasopharyngeal carcinoma: A multicenter, single-arm, phase 2 trial (DUBHE-N-302).
Journal of Clinical Oncology2024-06-013 citations
First-in-human phase I/Ib study of QL1706 (PSB205), a bifunctional PD1/CTLA4 dual blocker, in patients with advanced solid tumors
Journal of Hematology & Oncology2023-05-0839 citations